RET and cancer: Key targeted therapies include RET inhibitors like selpercatinib for RET rearrangements, ALK inhibitors like alectinib and crizotinib for ALK gene alterations, and EGFR inhibitors like osimertinib and erlotinib for EGFR-mutated cancers.